News
PCVX
88.39
+2.83%
2.43
Notable ETF Inflow Detected - IWM, FTAI, SFM, PCVX
NASDAQ · 1d ago
Franklin Biotechnology Discovery Fund Q3 2024 Commentary
Seeking Alpha · 1d ago
BlackRock Advantage Small Cap Growth Fund Q3 2024 Commentary
Seeking Alpha · 2d ago
Fidelity Select Health Care Portfolio Q3 2024 Fund Review
Seeking Alpha · 3d ago
Buy Rating on Vaxcyte Reaffirmed Amid Market Overreaction to Vaccine Policy Concerns
TipRanks · 4d ago
Weekly Report: what happened at PCVX last week (1111-1115)?
Weekly Report · 4d ago
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
Benzinga · 4d ago
RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up
Seeking Alpha · 11/15 11:02
Fidelity Small Cap Growth Fund Q3 2024 Review
Seeking Alpha · 11/15 07:50
Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
MarketWatch · 11/14 21:40
Vaccine makers fall after Trump nominates RFK to head HHS
TipRanks · 11/14 21:35
IWM, FTAI, SFM, PCVX: ETF Inflow Alert
NASDAQ · 11/12 15:51
Vaxcyte gets FDA Breakthrough Therapy Designation for its pneumococcal disease treatment
Seeking Alpha · 11/12 13:59
Vaxcyte provides regulatory updates on VAX-31 programs
TipRanks · 11/12 12:56
VAXCYTE INC: VAX-31 ADULT INDICATION: BREAKTHROUGH THERAPY DESIGNATION GRANTED BY FDA
Reuters · 11/12 12:30
VAXCYTE PROVIDES POSITIVE REGULATORY UPDATES ON VAX-31 PEDIATRIC AND ADULT PROGRAMS
Reuters · 11/12 12:30
Weekly Report: what happened at PCVX last week (1104-1108)?
Weekly Report · 11/11 09:21
Vaxcyte’s Strong Market Position and Financial Health Justify Buy Rating with $153 Target
TipRanks · 11/07 07:05
Vaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical Challenges
TipRanks · 11/07 06:00
Cantor Fitzgerald Reiterates Overweight on Vaxcyte
Benzinga · 11/06 14:43
More
Webull provides a variety of real-time PCVX stock news. You can receive the latest news about Vaxcyte, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.